COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN

被引：0

作者：

Shibahara, H. ^{[1
]}

Shiroiwa, T. ^{[2
]}

Nakamura, K. ^{[1
]}

Shimozuma, K. ^{[1
]}

机构：

[1] Ritsumeikan Univ, Kusatsu, Japan

[2] Natl Inst Publ Hlth, Saitama, Japan

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.jval.2013.08.532

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A415 / A416

页数：2

共 50 条

[1] REANALYSIS OF COST-EFFECTIVENESS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN USING A JAPANESE CLAIM DATA SET
Shibahara, H.
Shiroiwa, T.
Tange, C.
Nakamura, K.
Ozono, S.
Shimozuma, K.
VALUE IN HEALTH, 2014, 17 (03) : A85 - A86
[2] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY
Thompson, Melissa
Li, Tracy
Todd, Mary Beth
Yu, Margaret K.
Kheoh, Thian
He, Jianming
Saadi, Ryan
JOURNAL OF UROLOGY, 2014, 191 (04): : E810 - E810
[3] COST-EFFECTIVENESS OF NIRAPARIB PLUS ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Duru, E.
Mattingly, T. J.
Malone, D. C.
VALUE IN HEALTH, 2024, 27 (06) : S62 - S62
[4] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN THE REPUBLIC OF PANAMA, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL
Obando, C. A.
Desanvicente-Celis, Z.
Gonzalez, L.
Muschett, D.
Gonzalez, F.
Goldberg, P.
VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
[5] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN DOMINICAN REPUBLIC, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL
Obando, C. A.
Desanvicente-Celis, Z.
Gonzalez, L.
Muschett, D.
Gonzalez, F.
Goldberg, P.
VALUE IN HEALTH, 2014, 17 (07) : A635 - A635
[6] Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment
Aggarwal, Rahul
Harris, Anna
Formaker, Carl
Small, Eric J.
Molina, Arturo
Griffin, Thomas W.
Ryan, Charles J.
CLINICAL GENITOURINARY CANCER, 2014, 12 (05) : E167 - E172
[7] Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
Rudakova, A. V.
Meshkov, D. O.
Mishugin, S. V.
ONKOUROLOGIYA, 2014, 10 (03): : 73 - 77
[8] COST-EFFECTIVENESS EVALUATION OF ENZALUTAMIDE AND ABIRATERONE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
Gay, J. G.
Schultz, N. M.
Braun, S.
VALUE IN HEALTH, 2018, 21 : S29 - S30
[9] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, Elahe A.
CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
[10] An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy.
Li, Tracy
Thompson, Melissa
Todd, Mary Beth
Yu, Margaret K.
Kheoh, Thian San
He, Jianming
Saadi, Ryan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)

← 1 2 3 4 5 →